Navigation Links
Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
Date:6/2/2010

s or implied discussions regarding potential new indications or labeling for Afinitor or regarding potential future revenues from Afinitor. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Afinitor to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Afinitor will be approved for any additional indications or labeling in any market. Nor can there be any guarantee that Afinitor will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Afinitor could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or
'/>"/>
SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
5. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
6. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
11. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
(Date:8/21/2014)...  Seventy-one percent of Americans believe the abuse of strong ... health and safety issue in the United States ... by Repass & Partners, a Cincinnati ... severity of the prescription medication abuse problem and the need ... health situation facing our country," Rex Repass , CEO ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... Caremark (NYSE: CVS ) has been named ... by Reputation Institute, in partnership with Forbes Media. The ... RepTrak™ Pulse, a study that measures the 150 largest ... ) Of the companies included in ...
... -- American Oriental Bioengineering, Inc. (NYSE: AOB ) ... (the "NYSE") has notified the Company that it is not ... to timely file its Annual Report on Form 10-K with ... rules, when a Company does not comply with annual report ...
Cached Medicine Technology:CVS Caremark Ranks Among Top 25 Most Reputable Companies in America on Forbes List 2American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
(Date:8/22/2014)... Buying a policy for different life insurance products can ... coverage types by insurers in the U.S. The Quotes Pros ... the public using its sortable tool at http://quotespros.com/life-insurance.html . ... is expected to promote the discounts and special offerings for ... The system is designed to help an adult locate a ...
(Date:8/22/2014)... 22, 2014 The regional economy is ... is on the grow again. The plant ... summer 2016 to boost production of the popular Highlander ... Indiana’s overall investment to $4 billion. This step allows ... providing additional flexibility to adjust its product mix to ...
(Date:8/22/2014)... August 22, 2014 As the ... http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues to grow, ... companies have decided to limit coverage of uterine ... Telegram, Blue Cross-Blue Shield of Massachusetts will no ... involve morcellation as of September 1, 2014. Other ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced ... shorter progression free survival (PFS) in epidermal growth ... chemotherapy treated Asian patients. Also, BIM deletion independently ... , The BIM protein can activate the programmed ... in cells. BIM deletion has been detected in ...
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... developed by Dr. Sen and Dr. Samantha Pearson to ... glasses, contacts, and avoid corrective vision surgery by instead ... Shane Michaels, prompting an investigative review. , “There’s ... billions of dollars in revenue each year—it’s because people ...
Breaking Medicine News(10 mins):Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2
... 17 Addus HomeCare Corporation announced today that it has filed ... Exchange Commission (SEC) relating to a proposed initial public offering of ... and the price range for the offering have not yet been ... be offered by Addus HomeCare Corporation. , ...
... ... (TRACK™) is the first validated, parent-administered asthma-control test for preschool-aged children , ... Wilmington, DE (PRWEB) July 17, ... simple questions to determine if their child,s breathing problems are not under control. AstraZeneca ...
... , , WASHINGTON, July 17 ... nurses today hailed passage of a key amendment in the ... bill this morning that would enable individual states to go ... , Introduced by Rep. Dennis ...
... Could be targets for new treatments, researchers say , FRIDAY, ... genetic variants associated with high blood pressure in black Americans ... treat this major risk factor for heart disease and stroke. ... of PLoS Genetics , is one of a series ...
... , Patient Advocates , Medicare Beneficiaries Visit ... Act, Oppose Additional Cuts to Oxygen Benefit , ... of Congress to support patient-focused reform of the Medicare home oxygen ... (NECA), a national advocacy organization representing patients with chronic obstructive pulmonary ...
... Mass., July 17 The Hanover Insurance Group (NYSE: THG ... availability of a new product offering that can extend homeowners coverage to ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20051031/NEM023LOGO ... is more important than ever as the population of people residing in ...
Cached Medicine News:Health News:Addus HomeCare Corporation Files Registration Statement 2Health News:New Five-Question Test Helps Assess Asthma Control In Children Under Five Years Of Age 2Health News:New Five-Question Test Helps Assess Asthma Control In Children Under Five Years Of Age 3Health News:New Five-Question Test Helps Assess Asthma Control In Children Under Five Years Of Age 4Health News:RNs Praise House Vote to Permit State Single-Payer Laws 2Health News:RNs Praise House Vote to Permit State Single-Payer Laws 3Health News:Five Hypertension Genes Found in Black Americans 2Health News:Five Hypertension Genes Found in Black Americans 3Health News:Home Oxygen Patients and Family Members Visit Capitol Hill to Ask Congress to Protect Medicare Home Oxygen Therapy Benefit 2Health News:The Hanover Launches New Insurance Option to Protect Family Members in Assisted Living Facilities 2Health News:The Hanover Launches New Insurance Option to Protect Family Members in Assisted Living Facilities 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: